Cenderitide

Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research[1][2][3].

[1] Ichiki T, et al. Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. Int J Cardiol. 2019 Apr 15;281:166-171. DOI:10.1016/j.ijcard.2018.06.002
[2] Wojta J. Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states. Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):106-7. DOI:10.1093/ehjcvp/pvv043
[3] Lisa C Costello-Boerrigter, et al. Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure. BMC Pharmacol 11 (Suppl 1), P18 (2011).
[4] Lisy O, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008 Jul 1;52(1):60-8. DOI:10.1016/j.jacc.2008.02.077